Alan J. Korman
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune cells in cancer
Papers in
- Immunology 94
- Immunotherapy and Immune Responses 53
- Immune Cell Function and Interaction 40
- T-cell and B-cell Immunology 33
- Immune cells in cancer 9
- Oncology 79
- Cancer Immunotherapy and Biomarkers 67
- CAR-T cell therapy research 30
- Co-authors
- James Patrick Allison (6 shared papers)Karl S. Peggs (3 shared papers)Jack L. Strominger (12 shared papers)Mark Selby (13 shared papers)Sergio A. Quezada (2 shared papers)Nils Carl Lønberg (5 shared papers)Changyu Wang (5 shared papers)Tseng-hui Timothy Chen (3 shared papers)
- Journals
- Proceedings of the National Academy of Sciences (11 papers)Cancer Immunology Research (9 papers)Cancer Research (8 papers)Journal for ImmunoTherapy of Cancer (7 papers)The Journal of Immunology (7 papers)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Alan J. Korman
119 papers receiving 41.9k citations
Alan J. Korman's Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 28.1k
- Immunology 22.2k
- Cancer Research 2.3k
- Pulmonary and Respiratory Medicine 4.7k
- Genetics 1.4k
Countries citing papers authored by Alan J. Korman
This map shows the geographic impact of Alan J. Korman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan J. Korman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan J. Korman more than expected).
Fields of papers citing papers by Alan J. Korman
This network shows the impact of papers produced by Alan J. Korman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan J. Korman. The network helps show where Alan J. Korman may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan J. Korman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Hit paper breakdown → | 2012 | 10591 |
| 2 | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Hit paper breakdown → | 2012 | 6699 |
| 3 | Nivolumab plus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2013 | 3591 |
| 4 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Hit paper breakdown → | 2010 | 2584 |
| 5 | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Hit paper breakdown → | 2014 | 1703 |
| 6 | Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape Hit paper breakdown → | 2011 | 1414 |
| 7 | Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Hit paper breakdown → | 2003 | 853 |
| 8 | Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies Hit paper breakdown → | 2009 | 798 |
| 9 | Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells Hit paper breakdown → | 2013 | 741 |
| 10 | TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients Hit paper breakdown → | 2015 | 671 |
| 11 | The class II molecules of the human and murine major histocompatibility complex Hit paper breakdown → | 1984 | 608 |
| 12 | Evolving synergistic combinations of targeted immunotherapies to combat cancer Hit paper breakdown → | 2015 | 559 |
| 13 | 2008 | 539 | |
| 14 | In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates Hit paper breakdown → | 2014 | 533 |
| 15 | 1984 | 515 | |
| 16 | 2006 | 504 | |
| 17 | The foundations of immune checkpoint blockade and the ipilimumab approval decennial Hit paper breakdown → | 2021 | 443 |
| 18 | 2006 | 375 | |
| 19 | 2015 | 343 | |
| 20 | VISTA is an acidic pH-selective ligand for PSGL-1 Hit paper breakdown → | 2019 | 323 |
About Alan J. Korman
Alan J. Korman is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Virology and Immunology and Allergy, having authored 121 papers that have together received 43.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (67 papers), Immunotherapy and Immune Responses (53 papers), Immune Cell Function and Interaction (40 papers), T-cell and B-cell Immunology (33 papers), CAR-T cell therapy research (30 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Immune cells in cancer (9 papers) and Glycosylation and Glycoproteins Research (5 papers). The work is most often cited by research in Oncology (28.1k citations), Immunology (22.2k citations), Cancer Research (2.3k citations), Pulmonary and Respiratory Medicine (4.7k citations) and Genetics (1.4k citations). Alan J. Korman has collaborated with scholars based in United States, Germany and France. Frequent co-authors include James Patrick Allison, Karl S. Peggs, Jack L. Strominger, Mark Selby, Sergio A. Quezada, Nils Carl Lønberg, Changyu Wang, Tseng-hui Timothy Chen, Deborah A. Shackelford and John Engelhardt. Their work appears in journals such as Proceedings of the National Academy of Sciences, Cancer Immunology Research, Cancer Research, Journal for ImmunoTherapy of Cancer and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.